The liver-gut axis perspective: Exploring the pathogenesis of fatty liver

IF 4.7 3区 医学 Q1 PHARMACOLOGY & PHARMACY
Zonghui Yang , Jinbao Zhang , Xiaona Liu , Honggang Chen , Haijing Duan , Qian Wang , Wenlong Zhao , Ling Jin
{"title":"The liver-gut axis perspective: Exploring the pathogenesis of fatty liver","authors":"Zonghui Yang ,&nbsp;Jinbao Zhang ,&nbsp;Xiaona Liu ,&nbsp;Honggang Chen ,&nbsp;Haijing Duan ,&nbsp;Qian Wang ,&nbsp;Wenlong Zhao ,&nbsp;Ling Jin","doi":"10.1016/j.ejphar.2025.177822","DOIUrl":null,"url":null,"abstract":"<div><div>Fatty liver is one of the most common chronic liver diseases globally, affecting approximately a quarter of the world's population. It poses a significant burden on global health. Its pathogenesis is highly complex. In recent years, increasing attention has been paid to exploring the pathogenesis of fatty liver from the perspective of the liver-gut axis. We first discuss the liver-gut axis in fatty liver, detailing the bidirectional communication between the liver and the intestines. Specifically, the liver releases primary bile acids and numerous bioactive mediators into the biliary tract and systemic circulation, which then interact with the intestine. Conversely, intestinal microorganisms and their metabolites are transported to the liver via the portal vein, thereby influencing liver function. In addition, the interactions between intestinal microbes, the host's immune system, and various soluble factors are described, including their contributions to fatty liver development. Second, we describe the mediators of communication between the intestine and the liver in the pathological state of fatty liver, focusing on three key substances: endotoxins, bile acids, and short-chain fatty acids. Third, we summarize the emerging treatments derived from the liver-gut axis in fatty liver, highlighting frontier findings that may lead to the development of novel therapies. Finally, we offer suggestions for future research directions. We hope that future studies will propose better research strategies for the interaction of the liver-gut axis to promote the development of new treatment strategies and the discovery of precise therapeutic targets for fatty liver.</div></div>","PeriodicalId":12004,"journal":{"name":"European journal of pharmacology","volume":"1002 ","pages":"Article 177822"},"PeriodicalIF":4.7000,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of pharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S001429992500576X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Fatty liver is one of the most common chronic liver diseases globally, affecting approximately a quarter of the world's population. It poses a significant burden on global health. Its pathogenesis is highly complex. In recent years, increasing attention has been paid to exploring the pathogenesis of fatty liver from the perspective of the liver-gut axis. We first discuss the liver-gut axis in fatty liver, detailing the bidirectional communication between the liver and the intestines. Specifically, the liver releases primary bile acids and numerous bioactive mediators into the biliary tract and systemic circulation, which then interact with the intestine. Conversely, intestinal microorganisms and their metabolites are transported to the liver via the portal vein, thereby influencing liver function. In addition, the interactions between intestinal microbes, the host's immune system, and various soluble factors are described, including their contributions to fatty liver development. Second, we describe the mediators of communication between the intestine and the liver in the pathological state of fatty liver, focusing on three key substances: endotoxins, bile acids, and short-chain fatty acids. Third, we summarize the emerging treatments derived from the liver-gut axis in fatty liver, highlighting frontier findings that may lead to the development of novel therapies. Finally, we offer suggestions for future research directions. We hope that future studies will propose better research strategies for the interaction of the liver-gut axis to promote the development of new treatment strategies and the discovery of precise therapeutic targets for fatty liver.

Abstract Image

肝肠轴视角:探讨脂肪肝的发病机制。
脂肪肝是全球最常见的慢性肝病之一,影响着大约四分之一的世界人口。它对全球卫生造成重大负担。其发病机制非常复杂。近年来,从肝肠轴的角度探讨脂肪肝的发病机制越来越受到重视。我们首先讨论脂肪肝的肝肠轴,详细说明肝肠之间的双向交流。具体来说,肝脏释放初级胆汁酸和许多生物活性介质进入胆道和体循环,然后与肠道相互作用。反之,肠道微生物及其代谢物通过门静脉转运到肝脏,从而影响肝功能。此外,还描述了肠道微生物、宿主免疫系统和各种可溶性因子之间的相互作用,包括它们对脂肪肝发展的贡献。其次,我们描述了脂肪肝病理状态下肠肝通讯的介质,重点介绍了三种关键物质:内毒素、胆汁酸和短链脂肪酸。第三,我们总结了脂肪肝中肝-肠轴的新兴治疗方法,突出了可能导致新治疗方法发展的前沿发现。最后,对今后的研究方向提出了建议。我们希望未来的研究能够对肝肠轴的相互作用提出更好的研究策略,以促进新的治疗策略的发展和对脂肪肝精确治疗靶点的发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
9.00
自引率
0.00%
发文量
572
审稿时长
34 days
期刊介绍: The European Journal of Pharmacology publishes research papers covering all aspects of experimental pharmacology with focus on the mechanism of action of structurally identified compounds affecting biological systems. The scope includes: Behavioural pharmacology Neuropharmacology and analgesia Cardiovascular pharmacology Pulmonary, gastrointestinal and urogenital pharmacology Endocrine pharmacology Immunopharmacology and inflammation Molecular and cellular pharmacology Regenerative pharmacology Biologicals and biotherapeutics Translational pharmacology Nutriceutical pharmacology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信